When Protection Becomes Permission: Inside the EPA’s Quiet Approval of Forever Chemicals

The EPA’s approval of a new forever chemical raises serious questions about environmental regulation, public health, and the repeating patterns behind chemical safety decisions that prioritize industry over long-term human and ecological wellbeing.

Under Trump EPA, Safe Formaldehyde Levels Nearly Double Amid Industry Influence

The EPA’s recent revision of formaldehyde safety thresholds nearly doubles the amount considered safe to inhale. Driven by former chemical industry insiders now within the agency, this shift signals a broader trend toward loosening regulations on carcinogens, raising concerns about public health and regulatory integrity.

The Quiet Case for Preventing Dementia Before It Starts

Dementia may not be an inevitable consequence of aging. Emerging evidence suggests that metabolic health, key nutrients, and dietary fat play a far greater role in preventing dementia naturally than most people realize.

The Hidden Impact of Constant Background Noise on Mental Health Most People Ignore

Constant background noise may be quietly affecting mental health, focus, and sleep—especially in apartment living. Here’s why silence matters more than we think.

Johnson & Johnson’s quiet pivot: drug price cuts and tariff relief signal a new era

Johnson & Johnson’s recent agreement with the Trump administration marks a key moment in U.S. drug pricing reform. By joining the TrumpRx platform and offering Medicaid pricing aligned with wealthy nations, the company gains tariff relief while promising significant price reductions. This deal signals a potential turning point in the complex balance between pharmaceutical profits, government policy, and patient access.